Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-Effectiveness Studies

Syeed, M Sakil; Ghule, Priyanka; Le, Lan; Veettil, Sajesh K.; Horn, Emily; Perdrizet, Johnna; Wasserman, Matt; Thakkinstian, Ammarin; Chaiyakunapruk, Nathorn

doi:10.1016/j.jval.2022.10.006

Cited by 15 publications

(14 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was generally followed by a decrease in invasive pneumococcal disease, pneumonia coded as bacterial and all‐cause pneumonia in children under 2 years of age. The effect was confirmed in several meta‐analyses 3–7 and a study published in 2022 showed that general vaccination was cost‐effective in both high‐income and middle‐income countries 8 …”

Section: Introductionmentioning

confidence: 81%

“…The effect was confirmed in several meta-analyses [3][4][5][6][7] and a study published in 2022 showed that general vaccination was cost-effective in both highincome and middle-income countries. 8 The 7-valent PCV (PCV7) was introduced to Stockholm in 2007 and was replaced by the 13-valent version (PCV13) in 2011. The coverage of PCV in the region has been stable over time, at 96%-97%.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The pneumococcal conjugate vaccine had a sustained effect on Swedish children 8 years after its introduction

Alfvén,

Bennet,

Granath

et al. 2024

Acta Paediatrica

View full text Add to dashboard Cite

AimThe pneumococcal conjugate vaccine, which covered seven serotypes of Streptococcus pneumoniae (PCV7), was introduced in Stockholm, Sweden, in 2007. It was replaced by a 13‐valent vaccine (PCV13) in 2011. We previously reported a decreased incidence of pneumonia and sinusitis among young children 4 years after the introduction of the PCV7. This study followed the incidence of pneumonia, sinusitis, mastoiditis and meningitis for four more years.MethodsWe studied validated hospital registry data covering children up to 17 years of age, who were hospitalised in the Stockholm region from 2003 to 2016, when the child population peaked at 485 687. All 11 115 cases diagnosed with pneumonia, coded as bacterial pneumonia, sinusitis, mastoiditis, bacterial meningitis or empyema, were identified. The controls had viral pneumonia or pyelonephritis.ResultsThe incidence rates for children under 2 years of age hospitalised for sinusitis, mastoiditis and meningitis decreased significantly by 61%–79% during the eight‐year post‐vaccination period. Hospitalisations for bacterial pneumonia decreased by 19%–25% in the same age group. These changes were probably due to both the vaccines and changes in diagnosis routines.ConclusionThe effect of vaccination on children under 2 years of age was sustained 8 years after the introduction of the pneumococcal conjugate vaccines.

show abstract

Section: Introductionmentioning

confidence: 81%

mentioning

confidence: 99%

The pneumococcal conjugate vaccine had a sustained effect on Swedish children 8 years after its introduction

Alfvén,

Bennet,

Granath

et al. 2024

Acta Paediatrica

View full text Add to dashboard Cite

show abstract

“…Routine childhood vaccination against seasonal influenza was cost-effective at I$3075.5 per QALY to EUR 1667.4 per QALY from a third-party payer’s perspective in Germany, as estimated by Scholz et al [ 36 ]. A meta-analysis performed by Syeed et al resulted in a pooled INB of I$53.49 (95% CI, 30.42–76.55) for low- and middle-income countries (LMIC) and of I$103.94 (95% CI, 75.28–132.60) for high-income countries for pneumococcal vaccination in children [ 37 ]. Quadrivalent influenza vaccination of the elderly population was cost-effective, according to the model of Jiang et al, if compared with no vaccination at a 29,580 threshold, as the ICER for the baseline scenario was I$6700 per QALY [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

Incremental Net Benefit and Incremental Cost-Effectiveness Ratio of COVID-19 Vaccination Campaigns: Systematic Review of Cost-Effectiveness Evidence

et al. 2023

View full text Add to dashboard Cite

SARS-CoV-2 vaccination has been the most effective tool to prevent COVID-19, significantly reducing deaths and hospitalizations worldwide. Vaccination has played a huge role in bringing the COVID-19 pandemic under control, even as the inequitable distribution of vaccines still leaves several countries vulnerable. Therefore, organizing a mass vaccination campaign on a global scale is a priority to contain the virus spread. The aim of this systematic review was to assess whether COVID-19 vaccination campaigns are cost-effective with respect to no vaccination. A systematic literature search was conducted in the WHO COVID-19 Global literature database, PubMed, Web of Science, Embase, and Scopus from 2020 to 2022. Studies assessing the COVID-19 vaccination campaign cost-effectiveness over no vaccination were deemed eligible. The “Drummond’s checklist” was adopted for quality assessment. A synthesis of the studies was performed through the “dominance ranking matrix tool”. Overall, 10 studies were considered. COVID-19 vaccination was deemed cost-effective in each of them, and vaccination campaigns were found to be sustainable public health approaches to fight the health emergency. Providing economic evaluation data for mass vaccination is needed to support decision makers to make value-based and evidence-based decisions to ensure equitable access to vaccination and reduce the COVID-19 burden worldwide.

show abstract

“… 5 , 6 In many of these decisions, PCV programs may be undervalued, which has been demonstrated by many economic evaluations of PCVs globally. 17 , 18 However, vaccine switches may also introduce implementation challenges from unaccounted resources consumed during vaccine transition activities and suboptimal transitions. 19 Implementation challenges could adversely affect vaccine access, produce negative public health impacts, and are important considerations for optimal resource allocation; 12 yet these are rarely included in current economic evaluations of pediatric vaccines.…”

Section: Introductionmentioning

confidence: 99%

“… 19 Implementation challenges could adversely affect vaccine access, produce negative public health impacts, and are important considerations for optimal resource allocation; 12 yet these are rarely included in current economic evaluations of pediatric vaccines. 18 …”

Section: Introductionmentioning

confidence: 99%

Implementation challenges and real-world impacts of switching pediatric vaccines: A global systematic literature review

Patikorn

Kategeaw

Perdrizet

et al. 2023

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Switching a vaccine for another on a pediatric national immunization program is often done for the betterment of society. However, if poorly implemented, switching vaccines could result in suboptimal transitions with negative effects. A systematic review was conducted to evaluate the existing knowledge from identifiable documents on implementation challenges of pediatric vaccine switches and the real-world impact of those challenges. Thirty-three studies met the inclusion criteria. We synthesized three themes: vaccine availability, vaccination program deployment, and vaccine acceptability. Switching pediatric vaccines can pose unforeseen challenges to health-care systems worldwide and additional resources are often required to overcome those challenges. Yet, the magnitude of the impact, especially economic and societal, was frequently under-researched with variability in reporting. Therefore, an efficient vaccine switch requires a thorough consideration of the added benefits of replacing the existing vaccine, preparation, planning, additional resource allocation, implementation timing, public–private partnerships, outreach campaigns, and surveillance for program evaluation.

show abstract

Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-Effectiveness Studies

Cited by 15 publications

References 109 publications

The pneumococcal conjugate vaccine had a sustained effect on Swedish children 8 years after its introduction

The pneumococcal conjugate vaccine had a sustained effect on Swedish children 8 years after its introduction

Incremental Net Benefit and Incremental Cost-Effectiveness Ratio of COVID-19 Vaccination Campaigns: Systematic Review of Cost-Effectiveness Evidence

Implementation challenges and real-world impacts of switching pediatric vaccines: A global systematic literature review

Contact Info

Product

Resources

About